Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.

Comparison of Provisional with Final Notifiable Disease Case Counts — National Notifiable Diseases Surveillance System, 2009

States report notifiable disease cases to CDC through the National Notifiable Diseases Surveillance System (NNDSS). This allows CDC to assist with public health action and monitor infectious diseases across jurisdictional boundaries nationwide. The Morbidity and Mortality Weekly Report (MMWR) is used to disseminate these data on infectious disease incidence. The extent to which the weekly notifiable conditions are overreported or underreported can affect public health understanding of changes in the burden, distribution, and trends in disease, which is essential for control of communicable diseases (1). NNDSS encourages state health departments to notify CDC of a case when initially reported. These cases are included in the weekly provisional counts. The status of reported cases can change after further investigation by the states, resulting in differences between provisional and final counts. Increased knowledge of these differences can help in guiding the use of information from NNDSS. To quantify the extent to which final counts differ from provisional counts of notifiable infectious disease in the United States, CDC analyzed 2009 NNDSS data for 67 conditions. The results of this analysis demonstrate that for five conditions, final case counts were lower than provisional counts, but for 59 conditions, final counts were higher than provisional counts. The median difference between final and provisional counts was 16.7%; differences were ≤20% for 39 diseases but >50% for 12. These differences occur for various diseases and in all states. Provisional case counts should be interpreted with caution and an understanding of the reporting process.

Reporting of cases of certain diseases is mandated at the state or local level, and states, the Council of State and Territorial Epidemiologists (CSTE), and CDC establish policies and procedures for submitting data from these jurisdictions to NNDSS. Not all notifiable diseases are reportable at the state level, and although disease reporting is mandated by legislation or regulation, state reporting to CDC is voluntary. States send reports of cases of nationally notifiable diseases to CDC on a weekly basis in one of several standard formats. Amended reports can be sent, as well as new reports. Cases are reported by week of notification to CDC. Cases reported each week to CDC and published in MMWR are deemed provisional. The NNDSS database is open throughout the year, allowing states to update their records as new information becomes available. Annually, CDC provides each state epidemiologist with a cutoff date (usually 6 months after the end of the reporting year) by which all records must be reconciled and no additional updates are accepted for that reporting period. After the database is closed, final case counts, prepared after the states have reconciled the year-to-date data with local reporting units, are approved by state epidemiologists as accurate reflections of final case counts for the year and are published in the MMWR Summary of Notifiable Diseases — United States. Data for 2009 were published in 2011 (2).

CDC's publication schedule allows states time to complete case investigation tasks. To examine the extent that provisional counts of infectious diseases differ from final counts, CDC compared the cumulative case counts published for week 52 of 2009 in the MMWR of January 8, 2010 to the case counts published in the NNDSS final data set for 2009 (cutoff date of June 2010) published in MMWR on August 20, 2010. To assess whether discrepancies between provisional and final counts were more common in specific states or regions, or everywhere, reporting was examined, by state, of four diverse diseases: one sexually transmitted disease (Chlamydia trachomatis, genital infection), one vaccine-preventable disease (pertussis), one foodborne disease (salmonellosis), and one vectorborne disease (Lyme disease). Data are not presented for tuberculosis and human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome because these data are published quarterly rather than weekly in MMWR. Weekly reports of these conditions to the public health community are of limited value because of differences in reporting patterns for these diseases, and long-term variations in the number of cases are more important to public health practitioners than weekly variations (3).

Reported data for 67 notifiable diseases were reviewed. Final counts were lower than provisional counts for five diseases, the same as provisional counts for three, and higher for 59 (Table 1). The median difference between final and provisional counts was 16.7%; differences were ≤20% for 39 diseases but >50% for 12. Among diseases with ≥10 cases reported in 2009, final counts were lower than provisional counts for just four: invasive Haemophilus influenzae disease, ages <5 years, unknown serotype (final: 166, provisional: 218); acute hepatitis C (final: 782, provisional: 844); toxic-shock syndrome, other than streptococcal (final: 74, provisional: 76); and influenza-associated pediatric mortality (final: 358, provisional: 360). Final counts were higher than provisional counts for 51 diseases. The greatest percentage differences between provisional and final case counts were for arboviral disease, West Nile virus (neuro/nonneuro) (final: 720, provisional: 0); mumps (final: 1,991, provisional: 982); and Hansen disease (final: 103, provisional: 59).

Examining four diverse but commonly reported diseases in detail revealed no consistent association between state or region and the magnitude of the discrepancy between final and provisional counts (Table 2). For Chlamydia trachomatis, genital infections, the final case count was 13.1% higher than the provisional count nationally; it was <2% lower everywhere and ≥20% higher in six states. Two states, Arkansas and North Carolina, reported no cases provisionally, but reported final case counts of 14,354 and 41,045, respectively. For Lyme disease, the final case count was 29.2% higher than the provisional count nationally. Only 23 jurisdictions reported >100 cases, including 21 states, upstate New York, and New York City. Of these, four states reported a final count lower than their provisional count (range: 13.4%–29.2%) and eight jurisdictions reported final counts ≥20% higher. The greatest percentage differences between provisional and final case counts were in Connecticut (final: 4,156, provisional: none), Minnesota, (final: 1,543, provisional: 169), Texas (final: 276, provisional: 48), and New York City (final: 1,051, provisional: 262). For pertussis, the final case count was 24.8% higher than the provisional count nationally; it was <2% lower everywhere and ≥20% higher in 18 states and the District of Columbia (DC). Of the five states that reported >1,000 cases, the states with the greatest percentage differences between provisional and final counts were Minnesota (final: 1,121, provisional: 165) and Texas (final: 3,358, provisional: 2,437). For salmonellosis, the final case count was 10.6% higher than provisional count nationally. Six states reported a final count lower than their provisional count (range: 0.1%–2.9%) and nine states plus DC reported final counts ≥20% higher, the highest being DC (final: 100, provisional: 26), Louisiana (final: 1,180, provisional: 599), and Indiana (final: 629, provisional: 349).

Reported by

Nelson Adekoya, DrPH, Div of Notifiable Diseases and Healthcare Information, Public Health Surveillance and Informatics Program Office; Henry Roberts, PhD, Div of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. Corresponding contributor: Nelson Adekoya, nba7@cdc.gov, 404-498-6258.

Editorial Note

The findings in this report corroborate previous observations that provisional NNDSS data should be interpreted with caution (1,4,5). The primary appeal of provisional counts is timeliness; in comparison, final counts are more complete and accurate. As additional information is collected during investigations, final case counts might be higher or lower than the provisional counts. Local and state health departments collect reportable surveillance data primarily to assist with disease control and prevention efforts (i.e., to monitor local outbreaks of infectious diseases), to measure disease burden among high-risk populations, and to assess effectiveness of local interventions. At the national level, these data can be compared with baseline data to detect unusual disease occurrences. Final data sets are useful in monitoring national trends and for determining the effectiveness of national intervention efforts. In 2009, final case counts did not differ from end-of-year provisional counts by >20% for two thirds of the 67 notifiable diseases examined. Understanding how provisional counts relate to final counts is essential for interpreting provisional data (6,7).

Final counts might be higher than provisional counts for several possible reasons: 1) as amended records are sent by states during the notification process, cases might be reclassified among confirmed, probable, suspected, and not-a-case categories; 2) states vary in their practices regarding when they report cases with incomplete data or that are under investigation, leading to variable delays; 3) allocation of cases to a state can be delayed; 4) laboratory testing, case investigation, and data entry can be delayed as a result of temporary staff absences (e.g., leave, furlough, or turnover); 5) states sometimes delay sending some reports to CDC until the end of the year; and 6) internal CDC data processing problems can cause a discrepancy.

The findings in this report are subject to at least one limitation. It was impossible to determine when final counts were known to the state and local jurisdictions so that they could take public health action. This report focuses only on counts published in MMWR. The jurisdictions might have been aware of final case counts sooner, and only notification to CDC was delayed. Although this study examined 1 year of data, previous research using multiple years of data for hepatitis A and B concluded that provisional data generally tend to underrepresent the final data counts for those conditions (1). The addition of more years to the current research, which examined multiple notifiable conditions and documents substantial differences across states, regions, and numerous conditions, would not be expected to change the overall results.

Interpreting weekly incidence data is complex because of surveillance system limitations. Nonetheless, health practitioners have to respond to public health threats based on preliminary surveillance information. In 2006, CDC and CSTE reconsidered data presentation formats and included additional information (e.g., 5-year weekly average, previous 52 weeks median, and maximum number of cases) to aid interpreting these data (3). However, the findings in this report illustrate that major challenges still exist in presenting and interpreting provisional data and highlights the need to examine specific factors that can contribute to late reporting of cases (e.g., late case reporting by providers to health departments or late reporting of cases by health departments to CDC) (4). Although information technology has improved notifiable disease reporting (8), NNDSS data remain subject to reporting artifacts. Understanding specific reasons for the variation between the provisional and final case counts for each condition can improve the use of provisional data for disease surveillance and notification.

Acknowledgments

Richard Hopkins, MD, Florida Dept of Health. John Davis-Cole, PhD, District of Columbia Dept of Health. Michael Landen, MD, New Mexico Dept of Health. Participating state health departments and reporting jurisdictions.

References

  1. Smallman-Raynor M, Cliff AD, Haggett P, Stroup DF, Williamson GD. Spatial and temporal patterns in final amendments to provisional disease counts. J Public Health Manag Pract 1999;5:68–83.
  2. CDC. Summary of notifiable diseases—United States, 2009. MMWR 2011;58(53).
  3. CDC. Notice to readers: changes in presentation of data from the National Notifiable Diseases Surveillance System. MMWR 2006;55:13–4.
  4. Stroup DF, Williamson GD, Herndon JL, Karon JM. Detection of aberrations in the occurrence of notifiable diseases surveillance data. Stat Med 1989;8:323–9.
  5. Stroup DF, Wharton M, Kafadar K, Dean AG. Evaluation of a method for detecting aberrations in public health surveillance system data. Am J Epidemiol 1993;137:373–80.
  6. Birkhead G, Chorba TL, Root S, Klaucke DN, Gibbs NJ. Timeliness of national reporting of communicable diseases: the experience of the National Electronic Telecommunications System for Surveillance. Am J Public Health 1991;81:1313–5.
  7. Boehmer TK, Patnaik JL, Burnite SJ, Ghosh TS, Gershman K, Vogt RL. Use of hospital discharge data to evaluate notifiable disease reporting to Colorado's Electronic Disease Reporting System. Public Health Rep 2011;126:100–6.
  8. Silk BJ, Berkelman RL. A review of strategies for enhancing the completeness of notifiable disease reporting. J Public Health Manag Pract 2005;11:191–200.

What is already known on this topic?

Provisional counts of notifiable diseases usually differ from final counts; they are most often lower.

What is added by this report?

In 2009, finalized case counts were higher than the provisional case counts for 59 of 67 notifiable diseases. The median difference between final and provisional counts was 16.7%; differences were ≤20% for 39 diseases but >50% for 12. These differences occur, to a greater or lesser extent, for a wide variety of diseases and in all states.

What are the implications for public health practice?

Notifiable disease data are subject to case reclassification leading to undernotification or overnotification. Provisional case counts should be interpreted with caution because of the reporting process. The primary appeal of provisional counts is timeliness; in comparison, final counts are more complete and accurate.


TABLE 1. Comparison of provisional and finalized notifiable diseases data — National Notifiable Diseases Surveillance System, 2009

Disease

Final data

Provisional data

Absolute change

Change (%)

Anthrax

1

1

Arboviral disease, California serogroup (neuro/nonneuro)

55

41

14

(34.1)

Arboviral disease, Eastern equine (neuro/nonneuro)

4

4

0

(0.0)

Arboviral disease, Powassan (neuro)

6

1

5

(500.0)

Arboviral disease, St. Louis encephalitis (neuro/nonneuro)

12

10

2

(20.0)

Arboviral disease, West Nile virus (neuro/nonneuro)

720

720

Botulism, total

118

92

26

(28.3)

Brucellosis

115

100

15

(15.0)

Chancroid

28

25

3

(12.0)

Chlamydia trachomatis, genital infections

1,244,180

1,100,230

143,950

(13.1)

Cholera

10

8

2

(25.0)

Coccidioidomycosis

12,926

12,729

197

(1.5)

Cryptosporidiosis, total

7,654

6,652

1,002

(15.1)

Cyclosporiasis

141

123

18

(14.6)

Ehrlichiosis, Ehrlichia chaffeen

944

801

143

(17.9)

Ehrlichiosis, Ehrlichia ewingii

7

6

1

(16.6)

Ehrlichiosis, Anaplasma phagocytophilum

1,161

690

471

(68.3)

Ehrlichiosis, undetermined

155

122

33

(27.0)

Giardiasis

19,399

17,548

1,851

(10.6)

Gonorrhea

301,174

260,530

40,644

(15.6)

Haemophilus influenzae, invasive disease, all ages, both sexes

3,022

2,896

126

(4.4)

Haemophilus influenzae, invasive disease, ages <5 yrs, serotype b

38

25

13

(52.0)

Haemophilus influenzae, invasive disease, ages <5 yrs, nonserotype b

245

203

42

(20.7)

Haemophilus influenzae, invasive disease, ages <5 yrs, unknown serotype

166

218

–52

(–23.9)

Hansen disease

103

59

44

(74.6)

Hantavirus pulmonary syndrome

20

12

8

(66.7)

Hemolytic uremic syndrome postdiarrheal

242

210

32

(15.2)

Hepatitis A, viral, acute

1,987

1,849

138

(7.5)

Hepatitis B, viral, acute

3,405

3,020

385

(12.7)

Hepatitis C, viral, acute

782

844

–62

(–7.4)

Influenza-associated pediatric mortality

358

360

–2

(–0.6)

Legionellosis

3,522

3,145

377

(12.0)

Listeriosis

851

755

96

(12.7)

Lyme disease, total

38,468

29,780

8,688

(29.2)

Malaria

1,451

1,169

282

(24.1)

Measles, total

71

61

10

(16.4)

Meningococcal disease, all serogroups

980

887

93

(10.5)

Mumps

1,991

982

1,009

(102.8)

Pertussis

16,858

13,506

3,352

(24.8)

Plague

8

7

1

(14.3)

Polio

1

1

Psittacosis

9

9

0

(0.0)

Q fever, total

113

95

18

(19.0)

Rabies, animal

5,343

3,581

1,762

(49.2)

Rabies, human

4

4

0

(0.0)

Rocky Mountain spotted fever, total

1,815

1,393

422

(30.3)

Rubella

3

4

–1

(–25.0)

Rubella, congenital syndrome

2

1

1

(100.0)

Salmonellosis

49,192

44,468

4,724

(10.6)

Shiga toxin-producing Escherichia coli (STEC)

4,643

4,323

320

(7.4)

Shigellosis

15,931

14,581

1,350

(9.3)

Streptococcal disease, invasive group A

5,279

4,861

418

(8.6)

Streptococcal toxic-shock syndrome

161

125

36

(28.8)

Streptococcus pneumoniae, invasive disease, drug resistant, all ages

3,370

2,823

547

(19.4)

Streptococcus pneumoniae, invasive disease, drug resistant, ages <5 yrs

583

464

119

(25.7)

Streptococcus pneumoniae, invasive disease, nondrug resistant, ages <5 yrs

1,988

1,768

220

(12.4)

Syphilis, congenital

427

257

170

(66.2)

Syphilis, primary and secondary

13,997

12,833

1,164

(9.1)

Tetanus

18

14

4

(28.6)

Toxic-shock syndrome (other than streptococcal)

74

76

–2

(–2.6)

Trichinellosis

13

12

1

(8.3)

Tularemia

93

79

14

(17.7)

Typhoid fever

397

324

73

(22.5)

Vancomycin-intermediate Staphylococcus aureus (VISA)

78

70

8

(11.4)

Vancomycin-resistant Staphylococcus aureus (VRSA)

1

1

Varicella (chickenpox morbidity)

20,480

16,944

3,536

(20.9)

Vibriosis

789

593

196

(33.1)


TABLE 2. Comparison of provisional and final reported cases of notifiable diseases for selected conditions, by state and area — National Notifiable Diseases Surveillance System, United States, 2009

Area

Chlamydia

Lyme disease

Pertussis

Salmonellosis

Final

Provisional

Change (%)

Final

Provisional

Change (%)

Final

Provisional

Change (%)

Final

Provisional

Change (%)

United States

1,244,180

1,100,230

(13.1)

38,468

29,780

(29.2)

16,858

13,506

(24.8)

49,191

44,468

(10.6)

New England

40,776

39,850

(2.3)

12,440

6,314

(97.0)

626

592

(5.7)

2,174

2,110

(3.0)

Connecticut

12,127

11,532

(5.2)

4,156

56

48

(16.7)

430

406

(5.9)

Maine

2,431

2,386

(1.9)

970

894

(8.5)

80

78

(2.6)

121

119

(1.7)

Massachusetts

19,315

19,538

(–1.2)

5,256

3,662

(43.5)

358

348

(2.9)

1,155

1,159

(–0.4)

New Hampshire

2,102

1,633

(28.7)

1,415

1,156

(22.4)

76

76

(0.0)

261

243

(7.4)

Rhode Island

3,615

3,614

(0.0)

235

212

(10.9)

45

31

(45.2)

144

122

(18.0)

Vermont

1,186

1,147

(3.4)

408

390

(4.6)

11

11

(0.0)

63

61

(3.3)

Mid-Atlantic

159,111

154,989

(2.7)

16,346

16,691

(–2.1)

1,222

1,101

(11.0)

5,514

5,001

(10.3)

New Jersey

23,974

21,181

(13.2)

4,973

4,163

(19.5)

244

158

(54.4)

1,132

802

(41.2)

New York (Upstate)

33,722

32,099

(5.1)

4,600

4,179

(10.1)

265

252

(5.2)

1,370

1,321

(3.7)

New York City

58,347

59,370

(–1.7)

1,051

262

(301.2)

98

92

(6.5)

1,253

1,171

(7.0)

Pennsylvania

43,068

42,339

(1.7)

5,722

8,087

(–29.2)

615

599

(2.7)

1,759

1,707

(3.1)

Eastern North Central

197,133

167,016

(18.0)

2,969

2,359

(25.9)

3,206

2,990

(7.2)

5,169

4,597

(12.4)

Illinois

60,542

48,929

(23.7)

136

126

(7.9)

648

570

(13.7)

1,484

1,294

(14.7)

Indiana

21,732

21,111

(2.9)

83

62

(33.9)

392

338

(16.0)

629

349

(80.2)

Michigan

45,714

44,873

(1.9)

103

99

(4.0)

900

854

(5.4)

960

911

(5.4)

Ohio

48,239

34,036

(41.7)

58

56

(3.6)

1,096

1,096

(0.0)

1,407

1,407

(0.0)

Wisconsin

20,906

18,067

(15.7)

2,589

2,016

(28.4)

170

132

(28.8)

689

636

(8.3)

Western North Central

70,396

66,205

(6.3)

1,693

303

(458.8)

2,840

1,678

(69.3)

2,679

2,472

(8.4)

Iowa

9,406

9,311

(1.0)

108

96

(12.5)

235

192

(22.4)

408

398

(2.5)

Kansas

10,510

9,798

(7.3)

18

14

(28.6)

240

146

(64.4)

398

269

(48.0)

Minnesota

14,197

12,222

(16.2)

1,543

169

(813.0)

1,121

165

(579.4)

575

572

(0.5)

Missouri

25,868

25,698

(0.7)

3

3

(0.0)

1,015

975

(4.1)

656

667

(–1.7)

Nebraska

5,443

5,262

(3.4)

5

20

(–75.0)

141

141

(0.0)

341

337

(1.2)

North Dakota

1,957

1,769

(10.6)

15

30

29

(3.5)

103

73

(41.1)

South Dakota

3,015

2,145

(40.6)

1

1

(0.0)

58

30

(93.3)

198

156

(26.9)

South Atlantic

249,979

194,409

(28.6)

4,466

3,778

(18.2)

1,632

1,551

(5.2)

14,478

13,488

(7.3)

Delaware

4,718

4,718

(0.0)

984

952

(3.4)

13

13

(0.0)

142

137

(3.7)

District of Columbia

6,549

6,414

(2.1)

61

20

(205.0)

7

3

(133.3)

100

26

(284.6)

Florida

72,931

71,731

(1.7)

110

127

(–13.4)

497

500

(–0.6)

6,741

6,749

(–0.1)

Georgia

39,828

29,934

(33.1)

40

53

(–24.5)

223

194

(15.0)

2,362

2,365

(–0.1)

Maryland

23,747

22,138

(7.3)

2,024

1,775

(14,0)

148

134

(10.5)

803

784

(2.4)

North Carolina

41,045

96

63

(52.4)

220

223

(–1.4)

1,810

1,053

(71.9)

South Carolina

26,654

25,014

(6.7)

42

39

(7.7)

262

252

(4.0)

1,195

1,153

(3.6)

Virginia

30,903

30,881

(0.1)

908

579

(56.8)

222

198

(12.1)

1,095

1,004

(9.1)

West Virginia

3,604

3,579

(0.7)

201

170

(18.2)

40

34

(17.7)

230

217

(6.0)

Eastern South Central

92,522

87,926

(5.2)

41

36

(13.9)

803

760

(5.7)

3,077

2,937

(4.8)

Alabama

25,929

22,833

(13.6)

3

3

(0.0)

305

285

(7.0)

932

850

(9.7)

Kentucky

13,293

13,166

(1.0)

1

1

(0.0)

226

219

(3.2)

453

451

(0.4)

Mississippi

23,589

22,146

(6.5)

75

66

(13.6)

899

853

(5.4)

Tennessee

29,711

29,781

(–0.2)

37

32

(15.6)

197

190

(3.7)

793

783

(1.3)

Western South Central

162,915

136,836

(19.1)

278

48

(479.2)

3,993

2,882

(38.6)

6,411

4,751

(34.9)

Arkansas

14,354

369

278

(32.7)

615

607

(1.3)

Louisiana

27,628

25,308

(9.2)

149

90

(65.6)

1,180

599

(97.0)

Oklahoma

15,023

12,959

(15.9)

2

117

77

(52.0)

652

615

(6.0)

Texas

105,910

98,569

(7.5)

276

48

(475.0)

3,358

2,437

(37.8)

3,964

2,930

(35.3)

Mountain

80,476

73,912

(8.9)

57

44

(30.0)

1,019

890

(14.5)

3,028

2,812

(7.7)

Arizona

26,002

25,110

(3.6)

7

6

(16.7)

277

224

(23.7)

1,086

1,051

(3.3)

Colorado

19,998

16,362

(22.2)

1

1

(0.0)

231

233

(–0.9)

619

621

(–0.3)

Idaho

3,842

3,501

(9.7)

16

15

(6.7)

99

99

(0.0)

174

172

(1.2)

Montana

2,988

2,913

(2.6)

3

3

(0.0)

61

57

(7.0)

110

99

(11.1)

Nevada

10,045

9,743

(3.1)

13

5

(160.0)

24

9

(166.7)

252

173

(45.7)

New Mexico

9,493

8,947

(6.1)

5

5

(0.0)

85

66

(28.8)

369

325

(13.5)

Utah

6,145

5,466

(12.4)

9

7

(28.6)

220

181

(21.6)

321

283

(13.4)

Wyoming

1,963

1,870

(5.0)

3

2

(50.0)

22

21

(4.8)

97

88

(10.2)

Pacific

190,872

179,087

(6.6)

178

207

(–14.0)

1,517

1,062

(42.8)

6,662

6,300

(5.8)

Alaska

5,166

4,412

(17.1)

7

3

(133.0)

59

49

(20.4)

68

70

(–2.9)

California

146,796

139,689

(5.1)

117

154

(–24.0)

869

473

(83.7)

5,003

4,757

(5.2)

Hawaii

6,026

5,610

(7.4)

—*

—*

46

29

(58.6)

338

297

(13.8)

Oregon

11,497

10,245

(12.2)

38

35

(8.6)

252

246

(2.4)

433

416

(4.1)

Washington

21,387

19,131

(11.8)

16

15

(6.7)

291

265

(9.8)

820

760

(7.9)

* Not notifiable in Hawaii.



Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.


All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #